Medicus Pharma presented updates on its SkinJect® and Teverelix® programs at the 2026 Bio International Conference. SkinJect®, a dissolvable microneedle treatment for basal cell carcinoma and Gorlin Syndrome, showed promising Phase 2 results with significant tumor clearance rates and is advancing toward FDA approval. Teverelix®, a next-gen GnRH antagonist, is progressing in studies for advanced prostate cancer, urinary retention relapse, and endometriosis, including a precision medicine trial using UAE genomic data. These developments highlight Medicus' focus on innovative therapies addressing unmet medical needs with ongoing regulatory and clinical milestones ahead.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
